Redoxis

Redoxis is a Sweden-based preclinical CRO with a core focus on immunology and rare diseases, offering comprehensive drug efficacy testing in models of autoimmune and inflammatory conditions. Founded in 2009, the company combines academic-grade scientific rigor with a collaborative partnership model, providing services ranging from in vitro assays to complex in vivo studies and advanced tissue analysis. It serves global clients developing diverse therapeutic modalities, including small molecules, biologics, and cell/gene therapies, aiming to de-risk and accelerate their preclinical development. As a private, service-oriented company, Redoxis generates revenue through contracted research and is positioned in the growing preclinical outsourcing market.

Integrated preclinical research platform featuring well-characterized in vivo models of autoimmune/inflammatory disease, a suite of in vitro/ex vivo immunological assays (cytokine profiling, cell phenotyping), and advanced high-resolution biology services including quantitative histopathology, imaging, and single-cell RNA sequencing. The platform is designed for mechanistic insight and efficacy evaluation across therapeutic modalities.

Redoxis competes in the preclinical CRO market, facing large, diversified players like Charles River Laboratories and Labcorp, as well as other specialty CROs focused on immunology. Its differentiation lies in its deep academic roots in immunology, integrated service platform including single-cell analytics, and emphasis on personalized scientific partnership rather than transactional service.